Receipt of at least 1 dose of investigational product (etanercept) and participation for
approximately 96 weeks in study 0881A1-3338 (B1801014)
Personally signed and dated informed consent document (and assent document, as applicable)
indicating the subject (or legally representative/guardian) has been informed of all
pertinent aspects of the study.
Exclusion criteria for subject planning to continue investigational product:
withdrawal from investigational product in study 0881A1-3338 for any reason (safety or
History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma